A phase II trial of an intradermally administered MART-1gp100/tyrosinase peptide-pulsed dendritic cell vaccine matured with a cytokine cocktail for patients with metastatic melanoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Melanoma vaccine (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 21 May 2014 Biomarkers information updated
- 18 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 May 2010 Actual end date (June 2007) added as reported by ClinicalTrials.gov.